Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

The study, led by Professor Michael Dustin of the Kennedy Institute, NDORMS in collaboration with Dr Sudha Kumari at MIT furthers our understanding of the regulation of T cell activation – an essential part of our immune response to different types of diseases – and its dysfunction in WAS patients.

WAS is a rare serious disease affecting between 1 and 10 people in a million worldwide, usually male (90%). People suffering from WAS have abnormal or nonfunctional white blood cells (which are part of the immune system) and are at increased risk of developing several immune and inflammatory disorders. There is also a significant reduction in the size and number of platelets, causing those affected to bleed easily.

The condition is caused by mutations or defects in the WAS gene, responsible for giving the instruction to make the Wiskott-Aldrich Syndrome Protein (WASP).  WASP is known to be able to produce new actin cytoskeleton, a network of fibers that make up the cell's structural framework.  The new research identifies how WASP is involved in passing on signals from the surface of T cells through the actin cytoskeleton to the cells core.

Professor Dustin says: “This was a heroic effort by Dr. Kumari, which required an arsenal of new tools. This effort opens a way forward to much needed new therapeutics for WAS and more common immunological diseases such as allergies.”

Similar stories

The Duchess of Cornwall opens the new Marcela Botnar wing

A new building at the University of Oxford's Botnar Institute for Musculoskeletal Sciences has been opened by The Duchess of Cornwall.

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.